Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma

M. Klanova, L. Andera, J. Brazina, J. Svadlenka, S. Benesova, J. Soukup, D. Prukova, D. Vejmelkova, R. Jaksa, K. Helman, P. Vockova, L. Lateckova, J. Molinsky, BC. Maswabi, M. Alam, R. Kodet, R. Pytlik, M. Trneny, P. Klener,

. 2016 ; 22 (5) : 1138-49. [pub] 20151014

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000955

Grantová podpora
NV15-27757A MZ0 CEP - Centrální evidence projektů

PURPOSE: To investigate the roles of BCL2, MCL1, and BCL-XL in the survival of diffuse large B-cell lymphoma (DLBCL). EXPERIMENTAL DESIGNS: Immunohistochemical analysis of 105 primary DLBCL samples, and Western blot analysis of 18 DLBCL cell lines for the expression of BCL2, MCL1, and BCL-XL. Pharmacologic targeting of BCL2, MCL1, and BCL-XL with ABT-199, homoharringtonine (HHT), and ABT-737. Analysis of DLBCL clones with manipulated expressions of BCL2, MCL1, and BCL-XL. Immunoprecipitation of MCL1 complexes in selected DLBCL cell lines. Experimental therapy aimed at inhibition of BCL2 and MCL1 using ABT-199 and HHT, single agent, or in combination, in vitro and in vivo on primary cell-based murine xenograft models of DLBCL. RESULTS: By the pharmacologic targeting of BCL2, MCL1, and BCL-XL, we demonstrated that DLBCL can be divided into BCL2-dependent and MCL1-dependent subgroups with a less pronounced role left for BCL-XL. Derived DLBCL clones with manipulated expressions of BCL2, MCL1, and BCL-XL, as well as the immunoprecipitation experiments, which analyzed MCL1 protein complexes, confirmed these findings at the molecular level. We demonstrated that concurrent inhibition of BCL2 and MCL1 with ABT-199 and HHT induced significant synthetic lethality in most BCL2-expressing DLBCL cell lines. The marked cytotoxic synergy between ABT-199 and HHT was also confirmed in vivo using primary cell-based murine xenograft models of DLBCL. CONCLUSIONS: As homoharringtonine is a clinically approved antileukemia drug, and ABT-199 is in advanced phases of diverse clinical trials, our data might have direct implications for novel concepts of early clinical trials in patients with aggressive DLBCL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000955
003      
CZ-PrNML
005      
20250225094840.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-15-1191 $2 doi
024    7_
$a 10.1158/1078-0432.CCR-15-1191 $2 doi
035    __
$a (PubMed)26467384
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klanova, Magdalena $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic. magdalena.klanova@seznam.cz.
245    10
$a Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma / $c M. Klanova, L. Andera, J. Brazina, J. Svadlenka, S. Benesova, J. Soukup, D. Prukova, D. Vejmelkova, R. Jaksa, K. Helman, P. Vockova, L. Lateckova, J. Molinsky, BC. Maswabi, M. Alam, R. Kodet, R. Pytlik, M. Trneny, P. Klener,
520    9_
$a PURPOSE: To investigate the roles of BCL2, MCL1, and BCL-XL in the survival of diffuse large B-cell lymphoma (DLBCL). EXPERIMENTAL DESIGNS: Immunohistochemical analysis of 105 primary DLBCL samples, and Western blot analysis of 18 DLBCL cell lines for the expression of BCL2, MCL1, and BCL-XL. Pharmacologic targeting of BCL2, MCL1, and BCL-XL with ABT-199, homoharringtonine (HHT), and ABT-737. Analysis of DLBCL clones with manipulated expressions of BCL2, MCL1, and BCL-XL. Immunoprecipitation of MCL1 complexes in selected DLBCL cell lines. Experimental therapy aimed at inhibition of BCL2 and MCL1 using ABT-199 and HHT, single agent, or in combination, in vitro and in vivo on primary cell-based murine xenograft models of DLBCL. RESULTS: By the pharmacologic targeting of BCL2, MCL1, and BCL-XL, we demonstrated that DLBCL can be divided into BCL2-dependent and MCL1-dependent subgroups with a less pronounced role left for BCL-XL. Derived DLBCL clones with manipulated expressions of BCL2, MCL1, and BCL-XL, as well as the immunoprecipitation experiments, which analyzed MCL1 protein complexes, confirmed these findings at the molecular level. We demonstrated that concurrent inhibition of BCL2 and MCL1 with ABT-199 and HHT induced significant synthetic lethality in most BCL2-expressing DLBCL cell lines. The marked cytotoxic synergy between ABT-199 and HHT was also confirmed in vivo using primary cell-based murine xenograft models of DLBCL. CONCLUSIONS: As homoharringtonine is a clinically approved antileukemia drug, and ABT-199 is in advanced phases of diverse clinical trials, our data might have direct implications for novel concepts of early clinical trials in patients with aggressive DLBCL.
650    _2
$a zvířata $7 D000818
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a bifenylové sloučeniny $x aplikace a dávkování $7 D001713
650    _2
$a bicyklické sloučeniny heterocyklické $x aplikace a dávkování $7 D019086
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a harringtoniny $x aplikace a dávkování $7 D006248
650    _2
$a lidé $7 D006801
650    _2
$a difúzní velkobuněčný B-lymfom $x klasifikace $x farmakoterapie $x genetika $x patologie $7 D016403
650    _2
$a myši $7 D051379
650    _2
$a protein MCL-1 $x biosyntéza $x genetika $7 D064549
650    _2
$a nitrofenoly $x aplikace a dávkování $7 D009596
650    _2
$a piperaziny $x aplikace a dávkování $7 D010879
650    _2
$a protoonkogenní proteiny c-bcl-2 $x biosyntéza $x genetika $7 D019253
650    _2
$a sulfonamidy $x aplikace a dávkování $7 D013449
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
650    _2
$a protein bcl-X $x biosyntéza $7 D051020
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Andera, Ladislav $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Czech Republic. $7 gn_A_00006005
700    1_
$a Brazina, Jan $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Czech Republic.
700    1_
$a Svadlenka, Jan $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Czech Republic.
700    1_
$a Benesova, Simona $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Czech Republic.
700    1_
$a Soukup, Jan, $d 1963- $u Department of Patology and Molecular Medicine, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic. $7 xx0140786
700    1_
$a Prukova, Dana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Vejmelkova, Dana $u First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Jaksa, Radek $u Institute of Pathology, General University Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Helman, Karel $u Faculty of Informatics and Statistics, University of Economics, Prague, Czech Republic. $7 xx0260953
700    1_
$a Vockova, Petra $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Lateckova, Lucie $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Molinsky, Jan $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Maswabi, Bokang Calvin Lenyeletse $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Alam, Mahmudul $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 gn_A_00003252
700    1_
$a Kodet, Roman $u Department of Patology and Molecular Medicine, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Pytlik, Robert $u First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Trneny, Marek $u First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00001121 $t Clinical cancer research $x 1078-0432 $g Roč. 22, č. 5 (2016), s. 1138-49
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26467384 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20250225094837 $b ABA008
999    __
$a ok $b bmc $g 1180095 $s 961522
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 22 $c 5 $d 1138-49 $e 20151014 $i 1078-0432 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
GRA    __
$a NV15-27757A $p MZ0
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace